Thierry André, M.D. received his education and training in medical oncology at the University of Paris, France. Dr. André is currently Professor of Medical Oncology at the University Pierre et Marie Curie (UMPC), Paris VI, is Head of the Medical Oncology department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris (public hospital system of Paris), and is a research assistant of Cancer Biology and Therapeutics. He is the Founding member and General Secretary of the GERCOR (Multidisciplinary Oncology Research Group) and leads the colorectal task force of GERCOR, and also a Member of the Adjuvant Colon Cancer Endpoints (ACCENT) group. Dr. André’s main research interest is in gastrointestinal malignancies.
Dr. André has published more than 220 peer-reviewed articles in prestigious journals including New England Journal of Medicine, Lancet Oncology, the Journal of the American Medical Association (JAMA), the Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Annals of Surgical Oncology, and the European journal of Oncology.
Dr. André is a member of several scientific organizations including the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), and was chairman of the GI Cancer Board for Research (2008-2010) of the French National Institute (INCA). He is also on the Editorial board of Le Bulletin Du Cancer, an Expert at the French Drug Agency (AFFSAPS), and the Chairman of French participation in the IDEA study (International Duration Evaluation of Adjuvant Chemotherapy).
Dr. Dirk Arnold is currently Director of the Insituto CUF de Oncologia in Lisbon, Portugal. Prior to this, Dr. Arnold was Professor of Medicine at the University of Hamburg, where he held the position as Medical Director of the University Cancer Center (UCCH) until 2012, and before as Assistant Professor and Chair of the Gastrointestinal Cancer Unit at the Martin Luther University Halle-Wittenberg in Halle, Germany, where he also received his training as Medical Oncologist and a specialist in Palliative Care. From 2012 to 2015, he served as Director of the Department of Medical Oncology of the Klinik für Tumorbiologie at the University of Freiburg. In January 2016, he joined the CUF Hospitals in Lisbon, Portugal, as Director of Oncology Services.
Dr. Arnold’s main research interests include the treatment of gastrointestinal and genitourinary cancers, focusing on molecular-targeted therapies, immunotherapy, multimodal treatment strategies, and early drug developments. He is also interested in research network structures, the methodologies of clinical research, benefit evaluation procedures, and palliative and supportive care.
Dr. Arnold is a member of the Executive Board of the European Society for Medical Oncology (ESMO) and European Cancer Organization (ECCO); chairman of Colorectal Cancer Study Group of the German Society of Clinical Oncology (AIO); American Society of Clinical Oncology (ASCO); Task Force Colorectal Cancer of the European Organization for Research and Treatment of Cancer (EORTC) GI study group; German Cancer Society, and the German Society of Haematology and Medical Oncology (DGHO).
Dr. Arnold has (co-) authored more than 150 articles in peer-reviewed journals and several book chapters.
Marc Y. Donath, M.D. is Head of the Clinic for Endocrinology, Diabetes and Metabolism at the University Hospital of Basel, Switzerland, and Professor for Endocrinology at the University of Basel. Dr. Donath is internationally recognized for his contribution to the understanding of the pathogenesis of Type 2 diabetes. His main scientific contribution is the description of an inflammatory process underlying the failure of the pancreatic islet to produce sufficient amount of insulin in Type 2 diabetes. Dr. Donath’s research has contributed to the concept that the innate immune system is part of the regulation of metabolism. He has widely published in journals including the New England Journal of Medicine, Nature, and Cell.
Dr. George A. Fisher, Jr. is a medical oncologist and gastrointestinal specialist. Dr. Fisher is the Colleen Haas Chair at Stanford University School of Medicine where his clinical and research interests are focused on gastrointestinal malignancies, combined modality therapy in gastric, esophageal, pancreas and rectal cancers, immunotherapy, and translational research. He is a member of the Stanford Cancer Institute and has held numerous administrative appointments at the Stanford University School of Medicine including Director for the Cancer Clinical Trials Office (2004-2013).
Dr. Fisher is the Co-Chair on the Scientific Advisory Board for the Neuroendocrine Tumor Research Foundation, a Member of the Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network, Member and Treasurer for the Executive Committee of the North American Neuroendocrine Tumor Society, and the Vice Chair for the GI Committee for the ECOG-ACRIN Cancer Research Group.
Dr. Fisher completed his medical education at Stanford University and is Board Certified in Medical Oncology by the American Board of Internal Medicine. He is the National Chair of XBiotech’s Global, Fast-tracked Phase III study evaluating the Company’s lead product candidate for the treatment of advanced colorectal cancer.
Evangelos J. Giabmarellos-Bourboulis, M.D., Ph.D. is on the Faculty of Medicine of the University of Athens, Greece and has been an Associate Professor of Medicine at the 4th Department of Internal Medicine since 2012. He is an internist and is trained in Clinical Immunology and Infectious Diseases. His main research interests are the immunopathogenesis and immunointervention in sepsis. He has published numerous peer-reviewed manuscripts in this area. Dr. Giamarellos-Bourboulis also has conducted extensive research on inflammatory disorders, including Hidradentitis Suppurativa (HS). He recently completed a Phase II study using MABp1 to treat moderate to severe HS.
Andrew Hendifar, M.D., is the medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and co-director of Pancreas Oncology. He and his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors.
Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He also conducts research involving cachexia in cancer patients, and has developed a treatment protocol in pancreatic cancer cachexia. Dr. Hendifar is the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.
Dr. Hendifar's work has been published in prestigious journals, including the Lancet, Cancer, Journal of Clinical Oncology, and Clinical Cancer Research. Dr. Hendifar has displayed deep subject-matter knowledge in presentations for organizations such as the National Institutes of Health and the American Society of Clinical Oncology. His patient care has also been recognized, as he was named a "Top Doctor" in 2010 and has been listed a "Super Doctor” since 2013.
Alexander Knuth, M.D. is the Medical Director and Chief Executive Officer of the National Center for Cancer Care and Research at Hamad Medical Corporation. Dr. Knuth’s pioneering work in cancer immunology led to the discovery of multiple human cancer antigens including MAGE, the first of the so-called cancer/testis (CT) antigens that have been a primary target of vaccine strategies to date. He also played a pivotal role in the development of peptide-based vaccines and adjuvants, established immune-monitoring techniques, and discovered tumor escape mechanisms. He has received many awards, including the prestigious Johann-Georg-Zimmermann Medal. Dr. Knuth is a member of the Cancer Research Institute’s (CRI) Scientific Advisory Council, serves on the CLIP Grant Review Committee and is a member of CRI’s global clinical investigator network.
Razelle Kurzrock, M.D., is a board-certified medical oncologist and a renowned expert in precision medicine. Dr. Kurzrock currently serves as Senior Deputy Center Director for Clinical Science, Director at the Center for Personalized Cancer Therapy, Director of the Clinical Trials Office, and a Team Leader for Experimental Therapeutics at the Moores Cancer Center at UC San Diego. Dr. Kurzrock is known for developing one of the largest and best Phase 1 clinical trials programs in the nation while at the University of Texas MD Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT (Profile-Related Evidence Determining Individualized Cancer Therapy). This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized chances for response.
Dr. Kurzrock has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.
Dr. Kurzrock is also Chief of the Hematology & Oncology Division in the UC San Diego School of Medicine. She is a frequent speaker at national and international meetings, and her research has been widely published, with more than 600 peer-reviewed publications. Dr. Kurzrock earned her medical degree from the University of Toronto. She completed her residency at Tulane University and her fellowship in medical oncology at the University of Texas MD Anderson Cancer Center. She is board certified in internal medicine and medical oncology.
Dr. Mark E. Rupp is a Professor and Chief of the Division of Infectious Diseases in the Department of Internal Medicine at the University of Nebraska Medical Center. He is also the Medical Director of The Nebraska Medical Center Department of Infection Control & Epidemiology.
Dr. Rupp received his medical degree from Baylor College of Medicine in Houston, Texas and holds a B.S. degree in Chemical Engineering from the University of Texas at Austin. He completed internship and residency training in Internal Medicine and a Fellowship in Infectious Diseases at Virginia Commonwealth University in Richmond, Virginia.
Dr. Rupp is a Diplomate of the American Board of Internal Medicine in the subspecialty area of Infectious Diseases. Dr. Rupp is a Fellow of the American College of Physicians (FACP), the Infectious Diseases Society of America (IDSA), and the Society for Hospital Epidemiology of America (SHEA). Dr. Rupp is a member of the International Society on Staphylococci and Staphylococcal Infections. He is a Past-President of SHEA and a past-president of the American Society for Microbiology Division L (Infection Control/Hospital Epidemiology). Dr. Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention, National Institutes of Health, and the US Department of Veteran Affairs.
Dr. Rupp has published over 300 articles, chapters and abstracts. He frequently presents papers at national and international conferences, serves as a guest lecturer, and is an active teacher and researcher. Dr. Rupp’s research interests are in the areas of staphylococcal disease, healthcare-associated infections, and antimicrobial resistance.